Immatics (IMTX) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMTX shares.
View IMTX analyst ratings or view top-rated stocks.

4 brokerages have issued 1-year price targets for Immatics' stock. Their IMTX share price forecasts range from $12.00 to $26.00. On average, they expect the company's stock price to reach $19.75 in the next twelve months. This suggests a possible upside of 100.5% from the stock's current price.
View analysts price targets for IMTX or view top-rated stocks among Wall Street analysts.

Immatics' stock was trading at $8.71 at the beginning of the year. Since then, IMTX shares have increased by 13.1% and is now trading at $9.85.
View the best growth stocks for 2023 here.

Immatics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,420,000 shares, an increase of 28.1% from the April 30th total of 3,450,000 shares. Based on an average daily volume of 370,900 shares, the short-interest ratio is presently 11.9 days. Currently, 8.1% of the company's shares are sold short.
View Immatics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our IMTX earnings forecast.

Immatics (NASDAQ:IMTX) posted its earnings results on Tuesday, March, 21st. The company reported ($0.23) EPS for the quarter. The business earned $38.44 million during the quarter, compared to analysts' expectations of $13.18 million. Immatics had a negative net margin of 85.93% and a negative trailing twelve-month return on equity of 41.31%.

ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC),

Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).

Immatics trades on the NASDAQ under the ticker symbol "IMTX."

Immatics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (7.87%), Price T Rowe Associates Inc. MD (0.77%), Braidwell LP (0.42%), JPMorgan Chase & Co. (0.29%), Hudson Bay Capital Management LP (0.28%) and Governors Lane LP (0.17%).

Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMTX stock can currently be purchased for approximately $9.85.

Immatics (NASDAQ:IMTX) has a market capitalization of $755.20 million and generates $182.13 million in revenue each year. The company earns $39.53 million in net income (profit) each year or ($1.06) on an earnings per share basis.

The company employs 188 workers across the globe.

Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.immatics.com. The company can be reached via phone at 4.97072E+12.